arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2019-25-6-622-629arthyper-1889Research ArticleОРИГИНАЛЬНАЯ СТАТЬЯORIGINAL ARTICLEВлияниe эмпаглифлозина и вилдаглиптина на структурно-функциональные свойства сосудистой стенки у больных сахарным диабетом 2-го типаEffects of empagliflosin and vildagliptin on structural and functionak parametres in patients with type 2 diabeteshttps://orcid.org/0000-0003-0919-7607ВасильеваА. А.VasilievaA. A.

Васильева Анастасия Алексеевна — аспирантка кафедры кардиологии

ул. Аккуратова, д. 2, Санкт-Петербург, 197341

Anastasia A. Vasilieva, MD, PhD Student, Department of Cardiology

2 Akkuratov street, St Petersburg, 197341

vasileva_aa@almazovcentre.ruБабенкоА. Ю.BabenkoA. Yu.

Бабенко Алина Юрьевна — доктор медицинских наук, заведующая НИЛ диабетологии Института эндокринологии

Санкт-Петербург

Alina Yu. Babenko, MD, PhD, Head, Laboratory of Diabetology

babenko_ayu@almazovcentre.ruЛебедевД. А.LebedevD. A.

Лебедев Денис Андреевич — младший научный сотрудник НИЛ диабетологии Института эндокринологии

Санкт-Петербург

Denis A. Lebedev, MD, Junior Researcher, Research Laboratory of Diabetology

lebedev_da@almazovcentre.ruКолчановаЯ. А.KolchanovaYu. A.

Колчанова Яна Андреевна — ординатор Института эндокринологии

Санкт-Петербург

Yana A. Kolchanova, MD, Research Laboratory of Diabetology

kolchanova_yaa@almazovcentre.ruГлаватскихЕ. Р.GlavatskikhE. R.

Главатских Екатерина Руслановна — ординатор Института эндокринологии

Санкт-Петербург

Eketerina R. Glavatskikh, MD, Research Laboratory of Diabetology

glavatskikh_er@almazovcentre.ruБояриноваМ. А.BoyarinovaM. A.

Бояринова Мария Анатольевна — младший научный сотрудник научно-исследовательской лаборатории Эпидемиологии АГ

Санкт-Петербург

Maria A. Boyarinova, MD, Junior Researcher, Research Laboratory of Arterial Hypertension Epidemiology

boyarinova_ma@almazovcentre.ruАлиеваА. С.AlievaA. S.

Алиева Асият Сайгидовна — кандидат медицинских наук, руководитель Центра атеросклероза и нарушений липидного обмена

Санкт-Петербург

alieva_as@almazovcentre.ruКарелкинаЕ. В.KarelkinaE. V.

Карелкина Елена Викторовна — научный сотрудник НИЛ кардиомиопатий

Санкт-Петербург

Elena V. Karelkina, MD, Researcher, Research Laboratory for Cardiomyopathies

karelkina_ev@almazovcentre.ruМоисееваО. М.MoiseevaO. M.

Моисеева Ольга Михайловна — доктор медицинских наук, директор Института сердца и сосудов, главный научный сотрудник НИО некоронарогенных заболеваний сердца

Санкт-Петербург

Olga M. Moiseeva, MD, PhD, DSc, Director, Institute of the Heart and Vessels, Leading Researcher, Research Department for Non-Coronary Heart Diseases

moiseeva_om@almazovcentre.ruКонрадиА. О.KonradiA. O.

Конради Александра Олеговна — доктор медицинских наук, профессор, член-корреспондент Российской академии наук, заместитель генерального директора по научной работе

Санкт-Петербург

Aleхandra O. Konradi, MD, PhD, DSc, Professor, Corresponding Member of RAS, Deputy Director General on Science

konradi_ao@almazovcentre.ruФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research CentreRussian Federation201913122019256622629Copyright © Васильева А.А., Бабенко А.Ю., Лебедев Д.А., Колчанова Я.А., Главатских Е.Р., Бояринова М.А., Алиева А.С., Карелкина Е.В., Моисеева О.М., Конради А.О., 20202020Васильева А.А., Бабенко А.Ю., Лебедев Д.А., Колчанова Я.А., Главатских Е.Р., Бояринова М.А., Алиева А.С., Карелкина Е.В., Моисеева О.М., Конради А.О.Vasilieva A.A., Babenko A.Y., Lebedev D.A., Kolchanova Y.A., Glavatskikh E.R., Boyarinova M.A., Alieva A.S., Karelkina E.V., Moiseeva O.M., Konradi A.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1889

Цель исследования — изучить влияние терапии эмпаглифлозином и вилдаглиптином в течение 24 недель на параметры эндотелиальной функции и сосудистой жесткости у больных сахарным диабетом 2-го типа (СД2) без предшествующих сердечно-сосудистых событий. Материалы и методы. Обследовано 34 больных СД2 без предшествующих сердечно-сосудистых событий, которым инициирована терапия эмпаглифлозином, и 11 больных СД2, которые получали вилдаглиптин. Исходно и через 24 недели терапии проводилась оценка антропометрических параметров, индекса реактивной гиперемии (RHI) для оценки эндотелиальной функции, сосудистой жесткости, параметров центрального давления, ультразвукового исследования сонных артерий, а также оценка индекса массы миокарда левого желудочка методом эхокардиографии. Проведена оценка влияния эмпаглифлозина и вилдаглиптина на динамику структурнофункциональных параметров сосудистой стенки. Результаты. Через 24 недели терапии сахароснижающими препаратами отмечено статистически значимое увеличение RHI в группе эмпаглифлозина (р < 0,05) в отличие от группы вилдаглиптина. Заключение. Эмпаглифлозин обладает специфической способностью улучшать эндотелиальную функцию.

эмпаглифлозинвилдаглиптинэндотелиальная функциясосудистая жесткостьсахарный диабет 2-го типаempagliflozinvildagliptinendothelial functionarterial stiffnesstype 2 diabetes mellitusИсточник финансирования: грант Российского научного фонда № 17–75–30052 «Разработка персонализированной терапии ожирения и сахарного диабета 2-го типа в целях снижения сердечно-сосудистых рисков».The study was supported by the grant of the Russian Science Foundation, project № 17–75–30052.ReferencesAmerican Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl.1):S1–93.American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl.1):S1–93.Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222.Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222.Lunder M, Janic M, Sabovic M. Prevention of vascular complications in diabetes mellitus patients: focus on the arterial wall. Curr Vasc Pharmacol. 2018;17(1):6–15. doi: 10.2174/1570161116666180206113755Lunder M, Janic M, Sabovic M. Prevention of vascular complications in diabetes mellitus patients: focus on the arterial wall. Curr Vasc Pharmacol. 2018;17(1):6–15. doi: 10.2174/1570161116666180206113755Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness. A systematic review and meta-analysis. J Am Coll Cardiol. 2010;55 (13):1318–1327.Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness. A systematic review and meta-analysis. J Am Coll Cardiol. 2010;55 (13):1318–1327.Nilsson P, Boutouyrie P, Cunha P, Kotsis V, Narkiewicz K, Parati G et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. 2013;31(8):1517–1526.Nilsson P, Boutouyrie P, Cunha P, Kotsis V, Narkiewicz K, Parati G et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. 2013;31(8):1517–1526.Chow B, Rabkin SW. The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis. Heart Fail Rev. 2015;20(3):291–303.Chow B, Rabkin SW. The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis. Heart Fail Rev. 2015;20(3):291–303.Van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011;34(9):2072–2077.Van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011;34(9):2072–2077.Shah Z, Pineda C, Kampfrath T, Maiseyu A, Ying Z, Racoma I et al. Acute DPP-4 inhibition modulates tone through GLP- 1 independent pathways. Vascular Pharmacol. 2011;55 (1–3):111–117.Shah Z, Pineda C, Kampfrath T, Maiseyu A, Ying Z, Racoma I et al. Acute DPP-4 inhibition modulates tone through GLP- 1 independent pathways. Vascular Pharmacol. 2011;55 (1–3):111–117.Schmieder R, Raff U, Schmidt S, Kistner I, Friedrich S, Bramlage P et al. Effects of the DPP-4 inhibitor saxagliptin on early vascular changes in the retinal and systemic circulation. Eur Heart J. 2013;34(suppl.1):607. https://doi.org/10.1093/urheartj/eht307.P607Schmieder R, Raff U, Schmidt S, Kistner I, Friedrich S, Bramlage P et al. Effects of the DPP-4 inhibitor saxagliptin on early vascular changes in the retinal and systemic circulation. Eur Heart J. 2013;34(suppl.1):607. https://doi.org/10.1093/urheartj/eht307.P607Koren S, Shemesh-Bar L, Tirosh A, Peleg RK, Berman S, Hamad RA et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther. 2012;14 (7):561–567.Koren S, Shemesh-Bar L, Tirosh A, Peleg RK, Berman S, Hamad RA et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther. 2012;14 (7):561–567.Derosa G, Ragonesi PD, Carbone A, Fogari E, D’Angelo A, Cicero AF et al. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin Pharmacother. 2012;13(18):2581–2591.Derosa G, Ragonesi PD, Carbone A, Fogari E, D’Angelo A, Cicero AF et al. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin Pharmacother. 2012;13(18):2581–2591.Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):21172128.Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):21172128.Васюк Ю. А., Иванова С. В., Школьник Е. Л., Котовская Ю. В., Милягин В. А., Олейников В. Э. и др. Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике. Кардиоваскулярная терапия и профилактика. 2016;115(2):4–19. doi: 10.15829/1728-8800-20162-4-19.Vasyuk YA, Ivanova SV, Shkolnik EL, Kotovskaya YV, Milyagin VA, Oleynikov VE et al. Consensus of Russian experts on the evaluation of arterial stiffness in clinical practice. Cardiovascular Therapy and Prevention. 2016;15(2):4–19. doi: 10.15829/17288800-2016-2-4-19. In Russian.Pignoli P, Longo T. Evaluation of atherosclerosis with B-mode ultrasound imaging. J Nucl Med Allied Sci. 1988;32 (3):166–173.Pignoli P, Longo T. Evaluation of atherosclerosis with B-mode ultrasound imaging. J Nucl Med Allied Sci. 1988;32 (3):166–173.Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation. 1993;87(3, Suppl.):1156–1165.Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation. 1993;87(3, Suppl.):1156–1165.Tentolouris A, Eleftheriadou I, Tzeravini E, Tsilingiris D, Paschou SA, Siasos G et al. Endothelium as a therapeutic target in diabetes mellitus: from basic mechanisms to clinical practice. Curr Med Chem. 2019. doi: 10.2174/0929867326666190119154152Tentolouris A, Eleftheriadou I, Tzeravini E, Tsilingiris D, Paschou SA, Siasos G et al. Endothelium as a therapeutic target in diabetes mellitus: from basic mechanisms to clinical practice. Curr Med Chem. 2019. doi: 10.2174/0929867326666190119154152Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg Bet al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369:13171326.Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg Bet al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369:13171326.White WB., Bakris GL., Bergenstal RM, Cannon CP, Cushman WC, Fleck P et al, Examination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162:620–626White WB., Bakris GL., Bergenstal RM, Cannon CP, Cushman WC, Fleck P et al, Examination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162:620–626Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine. 2015;373(3):232–242. doi: 10.1056/NEJMoa1501352.Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine. 2015;373(3):232–242. doi: 10.1056/NEJMoa1501352.Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. doi: 10.1056/NEJMoa1504720.Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. doi: 10.1056/NEJMoa1504720.Lunder M, Janić M, Japelj M, Juretič A, Janež A, Šabovič M. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. Cardiovasc Diabetol. 2018;17(1):153. doi: 10.1186/s12933-018-0797-6Lunder M, Janić M, Japelj M, Juretič A, Janež A, Šabovič M. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. Cardiovasc Diabetol. 2018;17(1):153. doi: 10.1186/s12933-018-0797-6Bosch A, Ott C, Jung S, Striepe K, Karg MV, Kannenkeril D. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovasc Diabetol. 2019;18(1):44. doi: 10.1186/s12933019-0839-8Bosch A, Ott C, Jung S, Striepe K, Karg MV, Kannenkeril D. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovasc Diabetol. 2019;18(1):44. doi: 10.1186/s12933019-0839-8Kubota Y, Miyamoto M, Takagi G, Ikeda T, KirinokiIchikawa S, Tanaka K et al. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci. 2012;27(11):1364–1370. doi: 10.3346/jkms.2012.27.11.1364Kubota Y, Miyamoto M, Takagi G, Ikeda T, KirinokiIchikawa S, Tanaka K et al. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci. 2012;27(11):1364–1370. doi: 10.3346/jkms.2012.27.11.1364Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013;77(5):1337–1344.Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013;77(5):1337–1344.Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369 (14):1317–1326. doi: 10.1056/NEJMoa1307684Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369 (14):1317–1326. doi: 10.1056/NEJMoa1307684White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi: 10.1056/NEJMoa1305889White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi: 10.1056/NEJMoa1305889Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(6):232–242. doi: 10.1056/NEJMoa1501352Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(6):232–242. doi: 10.1056/NEJMoa1501352Oyama J, Murohara T, Kitakaze M, Ishizu T, Sato Y, Kitagawa K, PROLOGUE Study Investigators. The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: The PROLOGUE Randomized Controlled Trial. PLoS Med. 2016;13 (6):e1002051. doi: 10.1371/journal.pmed.1002051Oyama J, Murohara T, Kitakaze M, Ishizu T, Sato Y, Kitagawa K, PROLOGUE Study Investigators. The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: The PROLOGUE Randomized Controlled Trial. PLoS Med. 2016;13 (6):e1002051. doi: 10.1371/journal.pmed.1002051Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Inoue A, SAIS Study Group. A randomized controlled trial comparing the effects of sitagliptin and glimepiride on endothelial function and metabolic parameters: Sapporo Athero-Incretin Study 1 (SAIS1). PloS One. 2016;11(10):e0164255. doi: 10.1371/journal.pone.0164255Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Inoue A, SAIS Study Group. A randomized controlled trial comparing the effects of sitagliptin and glimepiride on endothelial function and metabolic parameters: Sapporo Athero-Incretin Study 1 (SAIS1). PloS One. 2016;11(10):e0164255. doi: 10.1371/journal.pone.0164255van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011;34(9):2072–2077. doi: 10.2337/dc10-2421van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011;34(9):2072–2077. doi: 10.2337/dc10-2421Cosenso-Martin LN, Giollo-Júnior LT, Fernandes LAB, Cesarino CB, Nakazonek MA, de Nassau Machado M et al. Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: A randomized controlled trial. Acta Diabetologica. 2018;55 (12):1237–1245.Cosenso-Martin LN, Giollo-Júnior LT, Fernandes LAB, Cesarino CB, Nakazonek MA, de Nassau Machado M et al. Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: A randomized controlled trial. Acta Diabetologica. 2018;55 (12):1237–1245.Kitao N, Miyoshi H, Furumoto T, Ono K, Nomoto H, Miya A et al. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). Cardiovasc Diabetol. 2017;16(1):125. doi: 10.1186/s12933-0170607-6Kitao N, Miyoshi H, Furumoto T, Ono K, Nomoto H, Miya A et al. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). Cardiovasc Diabetol. 2017;16(1):125. doi: 10.1186/s12933-0170607-6

The authors declare that there are no conflicts of interest present.